Carcinomas and Melanomas CTL Against Autologous and Allogeneic Peptide Epitopes That Can Elicit Specific Derived neu-Identification of New HER 2 /
暂无分享,去创建一个
O. Larsson | A. Sette | E. Appella | R. Kiessling | E. Celis | K. Malmberg | J. Charo | F. Salazar-Onfray | K. Kono | C. Hising | M. Petersson | Y. Rongcun | K. Evrin | H. Maes | L. Lan
[1] A. Sette,et al. Identification of HER2/neu‐derived peptide epitopes recognized by gastric cancer‐specific cytotoxic T lymphocytes , 1998, International journal of cancer.
[2] R. Kiessling,et al. Interferon gamma impairs the ability of monocyte-derived dendritic cells to present tumour-specific and allo-specific antigens and reduces their expression of CD1A, CD80 AND CD4. , 1998, Cytokine.
[3] H. Rammensee,et al. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. , 1998, Cancer research.
[4] A. Sette,et al. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. , 1998, Human immunology.
[5] A. Sette,et al. Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells. , 1997, Cancer research.
[6] R. Kiessling,et al. Conversion of In Vitro Cultured Human Monocytes into Effective Presenters of an HER2/neu‐Encoded CTL Peptide Epitope , 1997, Scandinavian journal of immunology.
[7] T. Eberlein,et al. The HER2/neu‐derived peptide p654–662 is a tumor‐associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes , 1997, European journal of immunology.
[8] J. Luck,et al. Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas. , 1997, Anticancer research.
[9] J. Sidney,et al. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. , 1997, Journal of immunology.
[10] R. Fulco,et al. The erbB 2 oncogene and chemotherapy: a mini-review. , 1997, Journal of chemotherapy.
[11] E. Halapi,et al. Mechanisms of escape from CD8+ T‐cell clones specific for the HER‐2/NEU proto‐oncogene expressed in ovarian carcinomas: Related and unrelated to decreased MHC class 1 expression , 1997, International journal of cancer.
[12] T. Eberlein,et al. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. , 1995, Journal of immunology.
[13] J. Wharton,et al. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines , 1995, The Journal of experimental medicine.
[14] W. Kast,et al. Induction and characterization of cytotoxic T‐lymphocytes recognizing a mutated p21ras peptide presented by HLA‐A*0201 , 1995, International journal of cancer.
[15] A. Sette,et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. , 1995, Journal of immunology.
[16] T. Eberlein,et al. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[17] J. Sidney,et al. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. , 1994, Molecular immunology.
[18] K. Sakaguchi,et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[19] K. Sakaguchi,et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes , 1994, The Journal of experimental medicine.
[20] A. Gazdar,et al. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. , 1994, Cancer research.
[21] R. Steinman,et al. Proliferating dendritic cell progenitors in human blood , 1994, The Journal of experimental medicine.
[22] J. Renauld,et al. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1994, The Journal of experimental medicine.
[23] R. Henderson,et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. , 1994, Science.
[24] F. Sallusto,et al. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha , 1994, The Journal of experimental medicine.
[25] H. Grey,et al. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[26] T. Eberlein,et al. HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. , 1993, Journal of immunology.
[27] J. Sidney,et al. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules , 1993, Cell.
[28] S. H. van der Burg,et al. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild‐type p53 , 1993, European journal of immunology.
[29] P. Coulie,et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1993, The Journal of experimental medicine.
[30] T. Eberlein,et al. T-cell recognition of ovarian cancer. , 1993, Surgery.
[31] Catia,et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E , 1992, The Journal of experimental medicine.
[32] P. Parham,et al. The HLA-A,B "negative" mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon. , 1992, Journal of immunology.
[33] J. Wharton,et al. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. , 1991, Cancer research.
[34] R. Freedman,et al. Cytotoxic T cell clones isolated from ovarian tumor-infiltrating lymphocytes recognize multiple antigenic epitopes on autologous tumor cells. , 1991, Journal of immunology.
[35] S. Rosenberg,et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.
[36] P. Cresswell,et al. Impaired assembly and transport of HLA‐A and ‐B antigens in a mutant TxB cell hybrid. , 1986, The EMBO journal.
[37] P. Seeburg,et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.